Glycopyrrolate/Formoterol Fumarate Fixed-Dose Combination Delivered by Metered Dose Inhaler Improves Lung Function and Symptoms in Patients with COPD: Results from the PINNACLE-4 Study in Asia, Europe, and the USA

被引：0
|
作者：
Lipworth, B. [1 ]
Collier, D. J. [2 ]
Gon, Y. [3 ]
Zhong, N. [4 ]
Nishi, K. [5 ]
Chen, R. [4 ]
Arora, S. [6 ]
Maes, A. [7 ]
Siddiqui, S. [8 ]
Reisner, C. [7 ]
Martin, U. J. [8 ]
机构：
[1] Univ Dundee, Ninewells Hosp, Scottish Ctr Resp Res, Dundee, Scotland
[2] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England
[3] Nihon Univ, Itabashi Hosp, Sch Med, Itabashi Ku, Tokyo, Japan
[4] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Dis,State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[5] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan
[6] Aventiv Res Inc, Columbus, OH USA
[7] Pearl Therapeut Inc, Morristown, NJ USA
[8] AstraZeneca, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4236
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALER, FORMULATED USING CO-SUSPENSION DELIVERY TECHNOLOGY, IMPROVES LUNG FUNCTION AND EXACERBATION OUTCOMES IN PATIENTS WITH COPD WITHOUT A RECENT HISTORY OF EXACERBATIONS: SUBGROUP ANALYSIS OF KRONOS STUDY
    Martinez, Fernando
    Ferguson, Gary
    Bourne, Eric
    Ballal, Shaila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    Reisner, Colin
    CHEST, 2019, 156 (04) : 2276A - 2277A
  • [32] Budesonide/glycopyrrolate/ formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Ballal, S.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    PNEUMOLOGIE, 2020, 74 : S44 - S44
  • [33] Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/ Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
    Rabe, K. F.
    Fabbri, L. M.
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2020, 74 : S44 - S44
  • [34] Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
    Rabe, K. F.
    Fabbri, L. M.
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [35] Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler Results from a non-interventional study
    Schmidt, O.
    Petro, W.
    Hoheisel, G.
    Kanniess, F.
    Oepen, P.
    Langer-Brauburger, B.
    RESPIRATORY MEDICINE, 2017, 131 : 166 - 174
  • [36] Beneficial Effect Of The Novel Lama/laba Co-Suspension Technology Of Glycopyrrolate/formoterol Fixed-Dose Combination Delivered By Mdi In Gold A And B COPD Patients: Pooled Analyses From Pinnacle-1 And-2
    Martinez, F. J.
    Rabe, K. F.
    Rodriguez-Roisin, R.
    Fabbri, L. M.
    Ferguson, G. T.
    Jones, P. W.
    Rennard, S. I.
    Siddiqui, S.
    Orevillo, C.
    Darken, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [37] Pooled Analyses From Pinnacle-1 And-2: The Novel Lama/laba Co-Suspension Technology Glycopyrrolate/formoterol Fixed-Dose Combination Delivered By Mdi Shows Improvement Versus Monocomponents In Patients With COPD
    Martinez, F. J.
    Rabe, K. F.
    Rodriguez-Roisin, R.
    Fabbri, L. M.
    Ferguson, G. T.
    Jones, P. W.
    Rennard, S. I.
    Siddiqui, S.
    Orevillo, C.
    Darken, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [38] The Novel Lama/laba Co-Suspension Technology Of Glycopyrrolate/formoterol Fixed-Dose Combination Mdi Significantly Improves Health Status In Symptomatic Patients With COPD
    Martinez, F. J.
    Fabbri, L. M.
    Ferguson, G. T.
    Orevillo, C.
    Darken, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [39] The Efficacy And Safety Of Aclidinium/formoterol Fixed-Dose Combination Compared With Salmeterol/fluticasone In Patients With COPD: Results From A Phase Iii Study
    Vogelmeier, C.
    Paggiaro, P.
    Dorca, J.
    Sliwinski, P.
    Mallet, M.
    Kirsten, A. -M.
    Seoane, B.
    Segarra, R.
    Leselbaum, A.
    Garcia Gil, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [40] A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease
    Colin Reisner
    Leonardo M. Fabbri
    Edward M. Kerwin
    Charles Fogarty
    Selwyn Spangenthal
    Klaus F. Rabe
    Gary T. Ferguson
    Fernando J. Martinez
    James F. Donohue
    Patrick Darken
    Earl St. Rose
    Chad Orevillo
    Shannon Strom
    Tracy Fischer
    Michael Golden
    Sarvajna Dwivedi
    Respiratory Research, 18
12345